Review
Oncology
Hao Zhang, Ziyu Dai, Wantao Wu, Zeyu Wang, Nan Zhang, Liyang Zhang, Wen-Jing Zeng, Zhixiong Liu, Quan Cheng
Summary: The regulatory mechanisms of PD-L1 and CTLA-4 play a crucial role in immunotherapy, and understanding their interactions can help improve patients' treatment responses and clinical care.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Immunology
Giuseppe Bronte, Alberto Verlicchi, Serena De Matteis, Alice Rossi, Alessandra Affatato, Francesco Giulio Sullo, Caterina Gianni, Matteo Canale, Marco Angelo Burgio, Angelo Delmonte, Michele Milella, Lucio Crino
Summary: Immune checkpoint inhibition has shown significant progress in treating non-small cell lung cancer patients, though resistance mechanisms like myeloid-derived suppressor cells and exhausted immune cells may limit effectiveness. Analyzing changes in immune cell subsets and disease progression during treatment could offer insights for developing new targets or biomarkers for cancer immunotherapy resistance.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Fabienne Mazerolles, Frederic Rieux-Laucat
Summary: The expression of co-signalling receptors on T cells plays a crucial role in regulating T cell responses, and an imbalance between activating and inhibitory signals may lead to autoimmunity. Research showed that activated TEFFs and TREGs express different co-signalling receptors, and the expression of PD-L1 on activated TEFFs is correlated with their proliferation.
Article
Oncology
Wenfeng Liu, Yang Liu, Cheng Hu, Cuiying Xu, Jiehong Chen, Yinting Chen, Jing Cai, Guangmei Yan, Wenbo Zhu
Summary: Oncolytic virotherapy can increase the number of Treg cells in the tumor microenvironment, while targeting Treg cells can enhance the anti-tumor effect of M1-based oncolytic virotherapy.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Integrative & Complementary Medicine
Qi Sun, Lin Xiao, Zhiying Cui, Yaping Yang, Junting Ma, Zhen Huang, Junfeng Zhang, Jiangning Chen
Summary: This study investigated the effects of 3,3'-diindolylmethane (DIM) on MDSCs and its therapeutic effect in conjunction with PD-1 antibody against tumor growth. It was found that DIM inhibits MDSCs and enhances the therapeutic effects of PD-1 antibody through promoting T cell responses.
Review
Oncology
Maximilian Haist, Henner Stege, Stephan Grabbe, Matthias Bros
Summary: Immunotherapy has shown benefits for advanced cancer patients, but many still do not respond to treatment. The accumulation of immunosuppressive cell populations like MDSC and Treg in the tumor microenvironment contributes to immune resistance and limits the effectiveness of immunotherapy.
Review
Biochemistry & Molecular Biology
Ching-Chuan Hsieh, Cheng-Chih Chang, Yung-Chien Hsu, Chun-Liang Lin
Summary: In the development of diabetic kidney disease, the dysregulation of glomerular cell types is crucial, and MDSCs exhibit anti-inflammatory activities that help improve renal fibrosis in diabetic mice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Si-Yuan Peng, Lei Chen, Rong-Hui Deng, Hao Li, Xin-Hua Liu, Di-Wei Zheng, Cong-Cong Wu, Chuan-Jun Liu, Zhi-Jun Sun, Xian-Zheng Zhang
Summary: The study introduces a novel nano-educator that instructs myeloid cells to assist T cells in revitalizing anti-PD-1 therapy. In vivo experiments demonstrate that the nano-educator can convert myeloid-derived cells into dendritic cells, essential for anti-PD-1 therapy, and promote T cells' contribution to the treatment.
Article
Biochemistry & Molecular Biology
Giorgia Fanelli, Marco Romano, Estefania Nova-Lamperti, Mariana Werner Sunderland, Alessandra Nerviani, Cristiano Scotta, Michele Bombardieri, Sergio A. Quezada, Steven H. Sacks, Randolph J. Noelle, Costantino Pitzalis, Robert I. Lechler, Giovanna Lombardi, Pablo D. Becker
Summary: PD-L1 signaling on memory T cells can induce their conversion into highly suppressive T cells, with reduced ERK phosphorylation and weakened AKT/mTOR/S6 signaling. However, T cells from rheumatoid arthritis patients may be refractory to down modulation of these pathways following PD-L1 cross-linking.
Article
Oncology
Adam N. R. Cartwright, Shengbao Suo, Soumya Badrinath, Sushil Kumar, Johannes Melms, Adrienne Luoma, Archis Bagati, Assieh Saadatpour, Benjamin Izar, Guo-Cheng Yuan, Kai W. Wucherpfennig
Summary: The study demonstrates that MDSCs do not block early steps of T-cell activation but induce DNA damage and p53 pathway activation in CD8(+) T cells through an iNOS-dependent pathway.
CANCER IMMUNOLOGY RESEARCH
(2021)
Review
Cell Biology
Houhui Shi, Kai Li, Yanghong Ni, Xiao Liang, Xia Zhao
Summary: T cell-based immunotherapy plays a crucial role in cancer treatment, but many patients still do not benefit from it. Researchers have identified myeloid-derived suppressor cells (MDSCs) as a key factor in immunotherapy resistance and are exploring combination therapies to improve efficacy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Oncology
Navid Sobhani, Dana Rae Tardiel-Cyril, Aram Davtyan, Daniele Generali, Raheleh Roudi, Yong Li
Summary: Immunotherapies have shown promise in cancer treatment but face challenges. Understanding the molecular mechanisms of immune checkpoint inhibitors and the role of regulatory T cells is crucial for improving cancer therapies.
Article
Oncology
Haixia Long, Qingzhu Jia, Liuyang Wang, Wenfeng Fang, Zhongyu Wang, Tao Jiang, Fei Zhou, Zheng Jin, Jiani Huang, Li Zhou, Chunyan Hu, Xinxin Wang, Jin Zhang, Yujie Ba, Yujie Gong, Xianghua Zeng, Dong Zeng, Xingxing Su, Peter B. Alexander, Li Wang, Limei Wang, Yisong Y. Wan, Xiao-Fan Wang, Li Zhang, Qi-Jing Li, Bo Zhu
Summary: This study reveals a mechanism by which tumors exploit anemia-triggered erythropoiesis for myeloid transdifferentiation and immunosuppression.
Article
Mathematics, Applied
Peng Feng, Menaka Navaratna
Summary: Regulatory T cells play a crucial role in immunotherapy, with their ratio to effector T cells impacting the prognosis of many cancers. The tug of war between regulatory T cells and effector T cells for interleukin-2 influences the immune response against cancer. Mathematical modeling demonstrates that the initial ratio between regulatory T cells and effector T cells affects tumor recurrence time, and utilizing IL-2 effectively can potentially alter the outcome of immunotherapy.
COMMUNICATIONS IN NONLINEAR SCIENCE AND NUMERICAL SIMULATION
(2021)
Article
Immunology
Joseph A. Pereira, Zachary Lanzar, Joseph T. Clark, Andrew P. Hart, Bonnie B. Douglas, Lindsey Shallberg, Keenan O'Dea, David A. Christian, Christopher A. Hunter
Summary: At homeostasis, a significant proportion of activated Foxp3(+) T regulatory cells (T-regs), called eT(regs), co-express higher levels of PD-1 and CTLA-4. Short term blockade of PD-1 or CTLA-4 pathways increases eT(reg) populations, while combined blockade of both pathways has an additive effect. Mechanistically, combined blockade decreases suppressive phospho-SHP2 Y580 in eT(reg) cells, leading to increased proliferation, enhanced IL-10 production, and reduced expression of CD80 and MHC-II in dendritic cells and macrophages. Therefore, targeting PD-1 and CTLA-4 pathways in T-reg cells can be useful in modulating inflammation.
FRONTIERS IN IMMUNOLOGY
(2023)